By Dr. Eddie Fat-Off (Eddie Fatakhov M.D.), author of “Dr. Fat-Off Simple Life-Long Weight-Loss Solutions.”
Thanks to celebrity endorsements and media exposure, Intermittent Fasting (IF) has grown in popularity in recent years. However, before you take fasting on as a weight loss solution or a way to cure diseases such as diabetes, it is important to understand why and how IF can affect your body – both positively and negatively.
What is Intermittent Fasting?
Some people mistake IF with starvation. Starvation occurs due to extreme hunger or lack of food. IF is a controlled cycling between periods of eating and not eating while food is readily available.
How do you Intermittently Fast?
Because IF is a practice unique to each individual there is no set duration or set of rules to follow. For instance, some might fast between breakfast and dinner for a predetermined amount of time. This is why many think of fasting as a way of life.
Why would you Intermittently Fast?
A good amount of research has been done to determine what the benefits of IF are. While there are varying opinions where IF is concerned these are the main benefits most can agree on:
1.) Weight Loss
IF is believed to cause weight loss because periods of not eating lowers insulin levels. Insulin is a hormone that allows our bodies cells to take in the glucose created by the break down of any carbohydrates we eat. This causes weight gain when that glucose is converted to fat and put into storage for future use.
During IF cells release the stored glucose to create the energy the body needs. This plus the overall lowering of calories eaten can result in weight loss.
2.) Possible Decreased Risk of Type 2 Diabetes
As previously discussed IF is believed to cause weight loss while lowering insulin levels. These two affects are key when it comes to type 2 diabetes since being obese or overweight with increasingly high insulin levels greatly increases the risk of developing this disease.
Unfortunately, this is where research is split. Some research has found evidence that IF could be beneficial for people at risk of developing type 2 diabetes while other research has found that IF can actually increase the risks through an increase in abdominal fat, bodily misuse of insulin, and muscle depletion (major risk factors for type 2 diabetes).
3.) A Healthier Heart
This report found that IF could reduce heart rate, blood pressure, cholesterol, and triglycerides (a fat linked the heart disease).
4.) A Healthier Brain
While studies on the affect IF has on humans are still needed IF seems to have promising benefits in the animal world. Studies have found IF can reduce the occurrence of neurological conditions such as Alzheimer’s disease, Parkinson’s, and even stroke.
5.) Reduced Cancer Risks
Animal studies are finding that IF can actually affect the rate of onset for tumors (human studies are needed).
The question becomes: To IF or not to IF?
For those thinking about IF but aren’t sure if they can do it, understand that you already experience a period of fasting every 24 hours when you sleep. As for incorporating IF into your daytime life I have one very important piece of advice for my readers.
Consult a physician before making big changes in your diet and routine. This conversation is very important when considering IF as a preventative measure or to encourage weight loss. With your doctor you can make a plan that would work best for you and your physical needs.
Eddie Fatakhov, M.D., a.k.a. Dr. Fat-off, is a Board-Certified Physician, Nutritionist, and Best-Selling Author of "The Doctors' Clinic-30 Program. His latest book is “Dr. Fat-Off Simple Life-Long Weight-Loss Solutions.”
New Year, New Career at DeafBlind Ontario Services
NEWMARKET, ON, Jan. 2, 2019 /CNW/ - Following the countdown, many begin the new year with the best of intentions. With 365 days of possibilities ahead, each new year presents a fresh slate and a time to set goals.
Resolutions that lead to meaningful change are rewarding and self-fulfilling. If you are searching for an opportunity to learn, grow, and contribute to another person's quality of life, consider pursuing a career as an intervenor.
Intervenors are specially trained professionals who act as the "eyes" and "ears" of the individual who is deafblind through the sense of touch. Deafblindness is a combined loss of vision and hearing to such an extent that neither sense can be used as a means of accessing information. This can impact communication, mobility, and a sense of inclusion in one's community.
Intervenors work with individuals who are deafblind, helping them learn through experience, empowering them to make informed decisions and be active participants in all areas of their lives. "DeafBlind Ontario Services offers a holistic approach, to empower each individual who is deafblind to achieve as much independence as possible," says Sarah, one of DeafBlind Ontario Services' intervenors.
Intervenors work in a variety of settings, in the community, residential or educational settings. Intervenors are leaders, problem solvers, and team players. They may be called on to employ their creativity and flexibility, and should be comfortable working closely with others.
Holly has worked as an intervenor at DeafBlind Ontario Services ever since graduating from the Developmental Services Worker (DSW) program at Loyalist College four years ago. "I am so honoured to support people who are deafblind. I feel a strong bond with each of the individuals I support; it is important to me to emphasize their strengths, abilities, and ultimately help them to achieve as much independence as possible," says Holly.
Whether you are graduating from high school or a post-secondary institution, or even considering a second career, exploring a role as an intervenor might be the solution for you. DSW, PSW, or SSW certifications are ideal credentials. However, DeafBlind Ontario Services will provide necessary training to individuals without these certifications too.
DeafBlind Ontario Services strives to be a top employer in the field by investing in their employees through extensive training, mentoring, and other professional development opportunities throughout all levels of the organization. DeafBlind Ontario Services has been awarded the designation of Nonprofit Employer of Choice two times, in 2015 and 2016. The Nonprofit Employer of Choice Awards (NEOC) recognizes organizations whose people leadership and vision has translated into exemplary talent management practices.
Intervenor Services is a sector that is currently experiencing growth and there is a shortage of trained intervenors. George Brown College's two-year program, Intervenor for Deafblind Persons, is currently the only in Ontario.
DeafBlind Ontario Services is hiring intervenors across the following areas: Ayr Barrie Embrun Georgina Kitchener London Oshawa Ottawa Peterborough
DeafBlind Ontario Services is a not-for-profit organization that helps individuals who are deafblind to increase their independence and improve their quality of life through specialized services. With programs across the province, their reach extends into a wide range of communities in Ontario.
GeneNews Expands Coverage by Commercial Health Insurance Networks
Signs Second Convertible Security Funding Agreement with Lind Asset Management for $500,000
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO THE UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./
TORONTO, Dec. 28, 2018 /CNW/ - GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company") today announced it has an agreement with Three Rivers Provider Network (TRPN) for Innovative Diagnostic Laboratory (IDL's) tests for early cancer detection. Three Rivers Provider Network is a rapidly growing proprietary provider network with 200 million lives that have access to IDL services through the TRPN network of providers, hospitals and ancillary facilities. The ability to address diagnostic gaps in early cancer detection saves lives and money for providers and patients in this network through access to IDL proprietary tests.
GeneNews/IDL has also entered into an agreement with MultiPlan Inc., one of the most comprehensive providers of healthcare cost management solutions that includes primary, complementary and out-of-network strategies for managing the financial risks associated with healthcare claims. MultiPlan contracts with 900,000 healthcare providers across the Unites States and has an estimated 60 million consumers accessing MultiPlan network products.
"We are pleased to announce that we are successfully establishing agreements with regional and national commercial health insurance networks, like Three Rivers and MultiPlan, resulting in expanded access to our four early cancer diagnostic tests – ColonSentry®, EarlyCDT®-lung, Prostate Health Index (phi) and BreastSentry," said James R Howard-Tripp, Chairman and CEO of GeneNews. "This expanded access is benefitting all parties - patients, their providers and ourselves, as more efficient processing of claims becomes fully established."
GeneNews/IDL is in discussion with several other regional and national commercial health insurance networks, as well as self-funded employer plans.
Additionally, GeneNews is preparing for a very active first Quarter in 2019, with plans already in place for screening of high-risk employee groups, implementation of screening within large healthcare groups and, collaborating with one or more large, physician networks. In addition, we will begin initial roll-out of the re-branding of our company which, together with an expanded Direct to Consumer focus, will allow us to more fully provide our early cancer diagnostic tests to the many patients who contact us.
Second Convertible Security Funding Agreement:
GeneNews has also entered into a second Convertible Security Funding Agreement (the "Agreement") with Lind Asset Management XI, LLC ("Lind") for CDN$500,000 in convertible securities.
Under the terms of the Agreement, Lind will advance CDN$500,000, less a closing fee of CDN$35,000, in consideration for the issuance by the Company of a convertible security with a face value of CDN$600,000 (the "Convertible Security"), which is expected to occur within ten (10) business days, subject to satisfaction of certain closing conditions.
"This injection of cash is welcome and will allow the Company to accelerate its initiatives with large healthcare providers to increase the rate of implementation, as well as begin rebranding. We are very pleased to have the partners within Lind continue to support us in this way," said Howard-Tripp.
The Convertible Security has a 30-month term from the date of issuance and bears interest of 8% per annum.
The Company's obligations under the Agreement are secured by all of the Company's present and after-acquired property other than intellectual property, including a pledge of its equity interests in its subsidiaries. In addition, the Company's indirect subsidiary, Innovative Diagnostic Laboratory, LLP, has pledged its present and after-acquired property, other than intellectual property.
Lind may convert the Convertible Security in monthly installments over the term at a conversion price equal to 85% of the 5-day trailing volume-weighted average price ("VWAP") of the Company's common shares on the TSX prior to the date that notice of conversion is provided by Lind. The Agreement contains restrictions on the amount of the Convertible Security that may be converted in any particular month and how many common shares of GeneNews Lind may hold at any given time. Lind is entitled to accelerate its conversion right to the full amount of the face value or demand repayment of the face value of the Convertible Security in cash upon a default and other specified events. To the extent that the full face value of the Convertible Security has not been converted at maturity, the balance of the face value is to be paid in cash at the end of the 30-month term.
The Company has the option to buy-back the Convertible Security in cash at any time by paying a buy-back premium equal to 5% of the outstanding balance of the Convertible Security.
In addition, the Company has agreed to issue 18,889,308 warrants to Lind in respect of the Convertible Security, exercisable for 36 months at an exercise price of $0.0344 per share. The number of warrants issued in connection with the Convertible Security are equal to 100% of the amount advanced by Lind ($500,000) divided by the VWAP of the common shares of the Company on the TSX for the five trading days immediately preceding the execution date of the Agreement. The Warrants provide for cashless exercise by the holder in the event that the Company ceases to be a foreign private issuer, as that term is defined under the United States Securities Act of 1933.
The Agreement and the issuance of the Convertible Security thereunder have been conditionally approved by the TSX and are subject to satisfaction of customary closing conditions.
About GeneNews
GeneNews, an innovator in the liquid biopsy space, is committed to becoming a leader in advanced diagnostics and personalized medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases. Our mission is to identify, assess and make commercially available a comprehensive menu of diagnostics that provide physicians and patients with personalized clinical intelligence and actionable information to improve health outcomes through the early diagnosis of disease. Our Richmond, Virginia-based Innovative Diagnostic Laboratory clinical reference lab specializes in traditional and advanced clinical evidence-based blood testing that helps find, understand, and address cancer risk in patient populations. Currently, IDL offers risk assessment blood tests for four prevalent cancer types - colorectal, lung, prostate and breast. GeneNews' common shares trade on the Toronto Stock Exchange under the symbol 'GEN'. More information on GeneNews and IDL can be found at www.GeneNews.com
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will", "may" and similar expressions, which reflect the Company's current expectations regarding future events, including with respect to advances under the Agreement, the conversion or buy-back of convertible securities, the Company's status as a foreign private issuer, the completion of the Note offering, the rate of implementation of corporate initiatives, adoption of tests and direct billing, and future cash flow sustainability. The forward-looking statements involve risks and uncertainties that could cause actual events to differ materially from those projected herein including the state of the equity capital markets, the receipt of required approvals, the future financial and operating performance of the Company and its subsidiaries, requirements for and availability of additional capital and the general business and political environment including in the healthcare sector. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
The holidays of 2018 have come and gone and, as many of us go back to work and are again surrounded by sniffling and coughing people, giving and receiving the ‘gift’ that keeps on giving: The Flu.
While it’s important to remember that ‘tis still the season for colds and flu, the good news is that if you follow these suggested preventions/precautions, the flu isn’t a give you have to receive.
Here are 10 simple ways to significantly decrease your chances of getting colds and even worse - the flu in 2019.
1.) Wash your hands
Think of every communal thing you touch on a daily basis - doors and door knobs, stair rails, other people, countertops, restaurant chairs… the list goes on and on. Because we are so hands-on the chances of spreading cold germs and flu virus is very high.
Combatting this spread is simple - wash your hands frequently and make sure you are doing it correctly!
2.) Clean communal surfaces
Many studies have been done to find the presence of viruses on shared surfaces in places like classrooms and airports. These studies all found breeding grounds for germs and viruses. While you might not be able to disinfect your schools and airports you can clean your home and office areas.
The use of a simple disinfectant wipe on light switches, doorknobs, phones, computer keyboards, and TV remotes can minimize exposure to germs and viruses for you, your loved ones, and your coworkers.
3.) Avoid touching your face, eyes and mouth
The best ways to transmit germs and viruses from surfaces and your hands is to touch your face - specifically your mouth and eyes. This direct introduction can lead to cold, flu, and other illness such as respiratory infection. So if you are a nail biter, sandwich eater, nose wiper, or eye rubber, either take a break from these actions or increase your hand washing even more.
4.) Use Hand Sanitizer
For those times when you don’t have access to soap and water grab the hand sanitizer. Hand sanitizer is a convenient and helpful tool for disinfecting your hands to prevent flu and cold viruses.
5.) Get Sleep
You immune system is your main line of defense against cold and flu and sleep deprivation is a major hindrance to your immune system. Not only will getting enough sleep help your body defend itself it will also increase your energy during the day.
6.) Exercise
In addition to helping you feel great working out is beneficial for a lot of reasons, including boosting your immune system. Reducing excess weight can be key when preventing colds and the flu since many studies have shown that overweight and obese people are more susceptible to injury and illness.
7.) Don’t be around sick people
If there is someone in your house or office who is coughing or sneezing try to keep your distance. This might be difficult at home (take all other precautions) but at work try suggesting the sick person stay home. Talking to your employer about making a plan for keeping sick people out of your workspace is a great way to keep employees healthy while also increasing productivity within a healthy workforce.
In addition - don’t be that guy. If you feel sick find a way to stay home.
8.) Cover your nose and mouth
Covering your nose and mouth while sneezing and coughing is a great way to prevent the flu and other serious respiratory illnesses, like respiratory syncytial virus (RSV), whooping cough, and severe acute respiratory syndrome (SARS), that are spread by cough, sneezing, or unclean hands. Remember to wash your hands after you cover!
9 & 10.) Eat healthy, stay hydrated and take probiotics
Eating a healthy diet and drinking plenty of water are two ways to support your hardworking immune system. Think fruits, vegetables, lean proteins like turkey, and complex carbohydrates when planning your meals.
In addition, increase your water intake to help your body flush toxins and add probiotics via diet or supplements to help fight any “bad” bacteria with “good” bacteria (recent studies have found that probiotics might help prevent upper respiratory infections in children).
11.) The flu shot
The CDC recommends getting a flu shot annually. Some studies have shown that the flu vaccine can decrease the chances of healthy adults contracting the flu by as much as 40% to 60%. While the flu vaccine isn’t guaranteed to prevent the flu for everyone some experts believe it can lessen the severity and duration of flu symptoms.
Eddie Fatakhov, M.D., a.k.a. Dr. Fat-off, is a Board-Certified Physician, Nutritionist, and Best-Selling Author of "The Doctors' Clinic-30 Program. His latest book is “Dr. Fat-Off Simple Life-Long Weight-Loss Solutions.”
NEWMARKET, ON, Dec. 21, 2018 /CNW/ - The holiday season is filled with distinct sights and sounds, imprinted in our memories and reinforced year after year.
Neighbourhoods aglow with twinkling lights, trees adorned with beautiful decorations, the energetic 'jingle' of bells, warm laughter of loved ones, and the unmistakable murmur of countless shoppers echoing through the mall. These are just a few of the many sights and sounds associated with the season.
However, for those with a limited range of senses, like combined vision and hearing loss, the holidays can be a time of darkness and silence.
When Shannon was born, her parents knew before leaving the hospital that their new baby was blind. Soon after, they made another discovery. "One morning when Shannon was just an infant, she didn't startle at a loud bang…I thought of Helen Keller immediately," said Shannon's Mom, Kim.
After an MRI, doctors confirmed that this discovery was not a coincidence; Shannon was diagnosed as being deafblind.
Deafblindness combines varying degrees of both vision and hearing loss, impacting access to information, communication, and mobility. In fact, 95% of what you learn comes from your eyes and ears.
With no useable vision in her right eye and a little peripheral vision in the left, in combination with no cochlea in the right ear and normal hearing in her left, Shannon's needs are complex and ever-changing.
For years, Shannon's family struggled to integrate her into the nearby school system and even tried a special education placement outside of their district. There were lots of challenges and limited success.
When Shannon was 11, she toured Brantford's W. Ross MacDonald School, which has a deafblind program. She loved it so much that she wanted to start there right away.
"As parents, our greatest fear was not finding the most appropriate and unique support Shannon needed once she graduated at 21. We started looking at supported living residences when she was 14. There were few options available, and, many would not have met our daughter's needs," said Kim.
"We found DeafBlind Ontario Services and added Shannon's name to their wait list right away. We really wanted Shannon to stay close to us, so we were thrilled when, in 2009, she moved into one of DeafBlind Ontario Services' locations in London."
Individuals who are deafblind have the capacity to build their life skills, gain independence, and contribute to the greater community with the support of professionally trained intervenors.
"With Shannon's unique needs, DeafBlind Ontario Services showed us that they too are unique and flexible in their approach."
Intervenors work with Shannon as a communication partner, bringing the world closer to her. "At this time of year, I am reminded of the time when Shannon did not want to take down her Christmas tree at the end of the holidays. The intervenors really embodied the spirit of the season and recognized that leaving it up would be more beneficial for her. That tree is now not only a Christmas tree, but Shannon's St. Paddy's Day tree, Easter tree, even a Halloween tree! This turned what could have been a negative experience, into such a positive one for Shannon."
"My family and I are grateful for the support Shannon receives from DeafBlind Ontario Services. They have made such a huge difference in our lives and Shannon's life. I don't think we would have all of the success that we've had without their great support and their expertise," said Kim.
DeafBlind Ontario Services is a not-for-profit organization that helps individuals who are deafblind to increase their independence and improve their quality of life through specialized services. With programs across the province, their reach extends into a wide range of communities in Ontario.
To help support individuals like Shannon and make a difference this holiday season, visit www.deafblindontario.com.
National #BecauseYouCare Campaign Planned for 2019 Aims to Raise Awareness of Social Isolation in Seniors Population
Unique Campaign Encourages Parliamentarians to Visit a Local Care Home
OTTAWA, Dec. 21, 2018 /CNW/ - On behalf of its members, the Canadian Association for Long-Term Care (CALTC) is urging all Members of Parliament across the country to help tackle social isolation among seniors. This first-of-a-kind initiative for CALTC aims to raise awareness about the negative impacts social isolation can have on the health of Canadian seniors.
CALTC will be calling upon on all Members of Parliament to visit at least one care home in their riding during the week of February 10 to 16th2019 which happens to coincide Valentine's Day. CALTC plans to post on its website a full listing of MPs who have advised us they plan to support the #BecauseYouCare campaign and have scheduled a visit to a local care home.
"As the holidays approach and we gather with close friends and family, we are reminded of the fact that many seniors live in isolation" says Daniel Fontaine, Chair of CALTC. "By reaching out to elderly family members or friends we can all make a huge difference in someone's quality of life. We certainly hope that next Valentine's Day a great number of MPs will take the time to visit a local care home and participate in this unique campaign."
Studies have shown that social isolation has a negative impact on health, especially among seniors, which increases the burden on the health care system. Social isolation among seniors can even occur in care homes where there are an abundance of residents and staff. We know that those who are more connected with their family and friends lead longer, happier and healthier lives. Over the holidays, Members of Parliament can help by booking time to visit a local care home.
Help spread the word over social media #BecauseYouCare
About the Canadian Association for Long Term Care
The Canadian Association for Long Term Care (CALTC) is a national organization comprised of provincial associations and long-term care providers that deliver publicly-funded health care services for seniors across Canada.
SOURCE Canadian Association for Long-Term Care
Child's Heartbeat Controls London Christmas Lights to Help Charity, Tiny Tickers
LONDON, Dec. 21, 2018 /CNW/ - London's shopping streets, the Seven Dials, located in the heart of the West End, will celebrate Christmas Lights with a difference this December.
The normally static lights are being connected to the heart monitor of Billy, a 2-year old heart patient using innovative new technology - so that they pulse in time with his heartbeat
The activity is to help shine a light on the plight of babies and children who miss Christmas due to serious heart conditions
Tiny Tickers, a small charity dedicated to helping improve the detection, care and treatment of babies with serious heart conditions, is highlighting that whilst everyone else is admiring the Christmas lights, many babies and young children face a very different Christmas; in hospital waiting for, or recovering from, open heart surgery.
Young Billy was diagnosed with Transposition of the Great Arteries (TGA) at his mum's 20 week scan. TGA is a condition where the two main blood vessels leaving the heart are swapped over and affects 1 in 10,000 babies. After a traumatic 13-hour operation at just 7 days old, Billy has come on in leaps and bounds.
Billy's mum commented on the activation: "Christmas is meant to be the happiest time of year but it's very easy to forget that lots of families could be going through a really hard time - and sadly they don't get to enjoy the holidays together."
"I really wanted to be involved in this idea because it's really important to keep making noise and raising awareness about heart disease -but also make people aware of the wider impact it has on families
"Thankfully we have incredible support from charities such as Tiny Tickers - but the funding doesn't magically appear, it relies on donations from the public. So I really hope this activation encourages people to donate - even if it's just a small amount."
Billy was born 9th May 2016, and had heart surgery on 16th May 2016
312 UK babies with a serious heart condition will be born over the Christmas period
1 in every 125 babies born in the UK has a heart defect
1,000 babies leave hospitals in the UK every year with an undetected heart condition
Charity Tiny Tickers calls for people to give the 'gift of hope' to a sick child by donating at Christmas
SOURCE Tiny Tickers
Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat
Licensing rights are worldwide excluding US, Canada, Japan and South America
LUGANO, Switzerland and FLORENCE, Italy, Dec. 21, 2018 /CNW/ - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and Menarini, an Italian biopharmaceutical Group active in 136 countries worldwide, today announced that Berlin Chemie AG, the German company of the Menarini Group, has been granted exclusive licensing rights to commercialize Pracinostat worldwide (excluding US, Canada, Japan and South America).
Pracinostat is an inhibitor of class I, II, and IV histone deacetylase. The compound is currently in development with a multiregional phase III trial in combination with Azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive induction chemotherapy; pracinostat is also being tested in an open label phase II study in combination with Azacitidine for the treatment of naïve patients with high risk myelodysplastic syndrome (MDS).
Under the terms of the agreement, Helsinn will retain all international development rights, including clinical development activities, and the supply of Pracinostat. Menarini will promote, distribute and commercialize Pracinostat in all countries of the assigned territories. Helsinn will retain the right to co-promote Pracinostat in the province of Shanghai, China, alongside Menarini, who will exclusively access the rest of China. Pursuant to certain clauses of the agreement, Menarini will have the opportunity to exploit any potential further oncology indication in the same territories.
Riccardo Braglia, Helsinn Group Vice Chairman and CEO, said: "We are pleased to have signed this agreement with Menarini, granting them exclusive licensing rights to promote and sell Pracinostat in AML, the prognosis of which remains dismal in those patients unfit to intensive induction chemotherapy.
We believe this global agreement will help to broaden the reach of Pracinostat to those patients who need it. Pracinostat, is now in Phase III clinical development. As Helsinn expands its focus into cancer therapeutics, we're delighted to have a new, trusted partner like Menarini on board."
"Finding new therapies against cancer, and precisely, against leukemia, is one of the goals of Menarini, which is strongly investing in Research and Development with the aim of discovering new products - said Lucia and Alberto Giovanni Aleotti, shareholders of the Menarini Group - We are extremely pleased to have signed this agreement with Helsinn, one of the recognized pharmaceutical companies in the field of cancer care products."
About Pracinostat
Pracinostat is an oral histone deacetylase ("HDAC") inhibitor that is in a pivotal Phase III study in combination with azacitidine for the treatment of adults with newly diagnosed acute myeloid leukemia ("AML") who are unfit for intensive induction chemotherapy. It is also being evaluated in a Phase II study in patients with high risk myelodysplastic syndrome ("MDS"). The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for pracinostat in combination with azacitidine for the treatment of patients with newly diagnosed AML who are ≥75 years of age or unfit for intensive chemotherapy.
In 2016 Helsinn obtained global rights to Pracinostat from MEI Pharma, Inc. under an exclusive license, development and commercialization agreement, the terms of which are not altered by the sublicense agreement, which also included the right for Helsinn to grant sublicenses to third parties.
Pracinostat is an investigational agent and is not approved for commercial use in the U.S. and any country worldwide.
About the Helsinn Group
Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco and China, as well as a product presence in approximately 190 countries globally.
Berlin-Chemie Menarini is a company of The Menarini Group, an Italian pharmaceutical company, 13th in Europe out of 5,345 companies, and 35th company in the world out of 21,587 companies, with a turnover of more than 3.6 billion Euro and 17,000 employees. The Menarini Group has always pursued two strategic objectives: research and internationalization, and has a strong commitment to oncology research and development. As part of such commitment to oncology, Menarini, is developing four investigational new oncological drugs. Two of them are biologics, namely the anti CD157 antibody MEN1112, and the toxin-conjugated, anti CD205 antibody MEN1309. In addition, Menarini has recently added two small molecules to its oncology pipeline, the dual PIM and FLT3 kinase inhibitor MEN1703, and the PI3K inhibitor MEN1611, in clinical development for the treatment of a variety of hematological and/or solid tumors. Menarini is active commercially in the most important therapeutic areas with products for cardiology, gastroenterology, pneumology, infectious diseases, diabetology, inflammation, and analgesia.
With 16 production sites and 7 Research and Development centers, the Menarini Group has a strong presence throughout Europe and Asia, Africa, Central and South America. Menarini Group products are available in 136 countries worldwide.
QUANTIC NANOTECH to Present First Digital Health Osteoarthritis Wearable Aid Treatment System at Las Vegas CES 2019
MADRID and LAS VEGAS, Dec. 21, 2018 /CNW/ - QUANTIC NANOTECH, a product division of Spanish DEMAC S.A. group has today announced the presentation in Eureka Park at CES 2019 of the first real wearable device for the aid, prevention and home treatment of osteoarthritis.
The new product is simple and convenient and can be used at home, controlled by any smartphone or as standalone IoT device, monitored remotely by medical personnel.
"Three years ago I was diagnosed with hand osteoarthritis. When I went to the hospital I found the treatment so cumbersome and complicated that I decided to create a more simple and efficient solution for everyone," said Jose Luis Torre DEMACgroup CEO and author of many international related published patents.
The product has been awarded internationally at various shows like InPEX Pittsburgh, ITEX Indonesia and 'Salon International des Inventions' Geneva and integrates cutting-edge technologies like memory shaped alloys and latest generation materials.
Dr. Juan Mulero MD Rheumatologist of the Ruber Internacional Hospital of Madrid said:
"The customized adaptation along with the possibility of applying topical treatments provided for this device can be very useful in hand osteoarthritis" who also declared: "This device is a way to apply at the same time and during the nightseveral modalitiesof treatment in the osteoarthritic hand. This disease is very common, because according to the Framingham Ostearthritis Study it produces in US symptoms of pain and deformity in 16% of women and in 8% of males. The local management of hand osteoarthritis combines both non-pharmacological and pharmacological approaches. Topical nonsteroidal anti-inflammatory drugs are recommended as a first-line pharmacological treatment, and splints might offer warmth, support and stabilization of joints."
QUANTIC NANOTECH has secured a seed capital investment already for the development of the product, and is looking for specialised Venture Capital for rapid worldwide implementation.
Rheumatism and osteoarthritis is a very common disease and is the major cause of sick leave worldwide with USD$ 304 Billions of total medical and earning losses just in the US alone approximately equivalent to 1% of US gross domestic product GDP (Source: arthritis.org - 2013).
AboutDEMAC S.A.
Established in 1992, DEMAC S.A. group is formed by a team of Engineers with passion for innovation that has been serving the consumer market in Spain and USA and has an extensive patent portfolio.
SOURCE QUANTIC NANOTECH
New partnership formed to improve lives of Albertans with digestive disease
CALGARY, Dec. 20, 2018 /CNW/ -The University Hospital Foundation (UHF), Ministry of Alberta Economic Development and Trade, and Shire Pharma Canada ULC (Shire Canada) through the Calgary Health Trust (CHT), have jointly invested $1.7 Million to create a pan-provincial Collaboration of Excellence to advance long-term health outcomes, quality of life, and economic prosperity for Albertans suffering with digestive diseases.
According to a recent National Digestive Disorders Prevalence and Impact Study, approximately two-thirds of Canadians suffer from digestive disorders. Often, people with digestive diseases suffer in silence or are treated with medication for their symptoms, with little understanding of how changes in nutrition may lead to significantly better health outcomes. To address this, Shire Canada, the Ministry of Economic Development and Trade, and the University Hospital Foundation recognized the need to invest in a new partnership for research and treatment of digestive diseases using nutrition-based therapies for the benefit of all Albertans.
Dr. Maitreyi Raman, Medical Director - Southern Alberta Home Enteral and Parenteral Nutrition Program, is the clinical lead on the project. "Our major objectives are to develop novel research to support the advancement of nutrition therapy in inflammatory bowel disease, develop novel nutrition and dietary therapies in the setting of liver cirrhosis, and then optimize how we provide care to patients with intestinal failure," said Dr. Raman.
About the AsCEND Collaboration
The provincial partnership for Alberta's Collaborations of Excellence for Nutrition in Digestive Diseases (AsCEND) is supported by an interdisciplinary team comprised of Shire Canada, the Government of Alberta, Alberta Health Services, the University of Alberta – Faculty of Medicine and Dentistry, and the University of Calgary.
AsCEND will support education and training, post-graduate physician nutrition fellowships, and clinical patient support and development, focused on three main pillars:
Discovery: Developing and evaluating nutrition-based therapies in gastrointestinal disease.
Patient Experience: Using personalized medicine to provide evidence-based nutrition care to patients with GI disease.
Knowledge Sharing: Providing nutrition-focused training and education to patients and practitioners, and advocating for enhanced nutrition delivery in acute and primary care.
"At Shire, we have long believed we have a unique opportunity to champion the underserved patient communities," said Eric Tse, General Manager for Shire Canada. "We are delighted to be a part of the AsCEND collaboration to help accelerate the development of new treatments and nutrition based therapies, remove obstacles to diagnosis and increase access to therapies that are so greatly needed for those who face digestive disease."
"Alberta is home to world-leading healthcare and research teams in gastroenterology, nutrition and inflammatory bowel diseases. The UHF is proud to be a partner in this collaboration as we know it will have a positive impact the health of Albertans living with these conditions", says Christy Holtby, Vice President, Strategic Partnerships with the University Hospital Foundation. "We're so grateful for the support from community members through our Foundation to help fund this ground-breaking collaboration."
"This partnership is an excellent example of how collaboration between the public and private sectors, and our foundations in both Edmonton and Calgary can work together to make a transformational impact on healthcare outcomes for Albertans," adds Dr. Chris Eagle, CEO of Calgary Health Trust. "We are pleased to have the opportunity to work alongside University Hospital Foundation and Shire Canada in bringing this opportunity to Alberta."
"Alberta's health innovators are making our province proud – attracting international attention and investment," says the Minister of Alberta Economic Development and Trade, Deron Bilous, "World-renowned life-sciences experts want to help our researchers and entrepreneurs create new products and businesses based on Alberta discoveries. That means healthier lives for people around the world – and new jobs and a more diversified economy here at home."
About the AsCEND Partners
The University Hospital Foundation raises and manages funds to advance patient care, research and healthcare education at the University of Alberta Hospital, the Mazankowski Alberta Heart Institute and the Kaye Edmonton Clinic. You can find more information at www.universityhospitalfoundation.ab.ca/.
The Ministry of Alberta Economic Development and Trade focuses on economic growth and diversification by supporting innovation and research; expanding access to capital for small and medium-sized enterprises; promoting trade, investment and market access initiatives; and leading Alberta's negotiations on trade agreements. Please visit our website at http://economic.alberta.ca
Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions. We seek to push boundaries through discovering and delivering new possibilities for patients across our portfolio of therapeutic areas including Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine, and Ophthalmics. For more information, please visit: www.shirecanada.com.
Calgary Health Trust raises money to advance healthcare within Calgary. Funds raised benefit Foothills Medical Centre, Peter Lougheed Centre, Rockyview General Hospital, South Health Campus, many community health programs and 12 Carewest care centres in our community. For more information about Calgary Health Trust and its strategic priorities, visit www.calgaryhealthtrust.ca.
Alberta Health Services is the provincial health authority responsible for planning and delivering health supports and services for more than four million adults and children living in Alberta. Its mission is to provide a patient-focused, quality health system that is accessible and sustainable for all Albertans.
